A single center experience with basiliximab induction therapy in renal transplantation.
Henry
M L
ML
The Ohio State University Medical Center, Department of Surgery, Division of Transplantation, Columbus, Ohio 43210, USA.
Pelletier
R P
RP
Elkhammas
E A
EA
Bumgardner
G L
GL
Ferguson
R M
RM
D000293:Adolescent; D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000077552:Basiliximab; D002102:Cadaver; D002648:Child; D005190:Family; D005260:Female; D006084:Graft Rejection / Q000517:prevention & control*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D016030:Kidney Transplantation / Q000276:immunology*; D019520:Living Donors; D008297:Male; D008875:Middle Aged; D011993:Recombinant Fusion Proteins; D012189:Retrospective Studies; D014019:Tissue Donors / Q000706:statistics & numerical data; D014184:Transplantation, Homologous; D044465:White People
D000911:Antibodies, Monoclonal; D007166:Immunosuppressive Agents; D011993:Recombinant Fusion Proteins; D000077552:Basiliximab